Fortrea Holdings Inc.

NASDAQ:FTRE

Biotechnology

Healthcare
$20.50 -0.46%

-$0.07 today

Market cap
$1.94B
Beta
2.11
P/E (TTM)
-3.1
EPS (TTM)
-$4.90
52W Low $4.36High $18.67

Volume 1.59M

Average 1.31M

FTRE Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Fortrea Holdings Inc.NASDAQ: FTRE

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures grows, but more slowly than its trailing trend

Q2 FY2026 capital expenditures of $9M (cash outflow) rose 20.0% year over year, behind the +106.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 12.5% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.

Context

  • Capital expenditures amounted to 0.9% of revenue in FY2025, unchanged from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +20.0% toward the trailing-twelve-month pace of +106.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$9M+12.5% QoQ
Last fiscal yearDec 2025
-$25.2M-1.2% YoY
LTMJun 2026
-$31.8M+106.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.0%——
1 year-1.2%——
3-year CAGR-22.6%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(25.2M) USD
Year-over-year change
+1.2%

Capital Expenditures vs competitors

How FTRE compares with its peers on the latest reported figures

  • FTRE's LTM Jun 2026 capital expenditures of $31.8M is the 2nd largest of the 3 companies compared; the peer median is $28.61M.
  • Its year-over-year change of +106.5% is the 2nd highest of 3, against a peer median of +269.9%.
  • Capital expenditures amounts to 1.2% of revenue for FTRE, versus a peer median of 1.2%.
FTRE Competitors Peer median
Capital Expenditures for FTRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MEDPMedpace Holdings, Inc.LTM Sep 2026$55.42M +625.1%-5.3%2.0%
FTREFortrea Holdings Inc.LTM Jun 2026$31.8M +106.5%-22.6%1.2%
CERTCertara, Inc.LTM Mar 2026$1.79M -85.3%+7.2%0.4%
Peer median (excluding FTRE) $28.61M+269.9%+1.0%1.2%

Competitors are the stored peer set for FTRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income98M186.2M(25.2M)(271.5M)(986.2M)
Depreciation & Amortization166.3M93.6M98M86.9M78M
Deferred Income Tax(30.2M)(16.5M)(41.6M)(24.6M)(32M)
Stock-Based Compensation27.5M25.4M42.7M58.4M74.4M
Change in Working Capital(127.2M)(248.2M)26.9M364.5M114.7M
Accounts Receivables(187.6M)(108.4M)(53.4M)309.9M70.9M
Inventory00000
Accounts Payables(6.2M)24.8M55.3M7.2M(109.9M)
Other Working Capital66.6M(164.6M)25M47.4M153.7M
Other Non-Cash Items35.4M42.2M67.6M49.1M864.6M
Operating Cash Flow169.8M82.7M168.4M262.8M113.5M
Capital Expenditures(26.5M)(54.4M)(40.3M)(25.5M)(25.2M)
Acquisitions (Net)000276.6M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities300K400K8.5M500K39.6M
Investing Cash Flow(26.2M)(54M)(31.8M)251.6M14.4M
Debt Repayment001.62B(482.7M)(76.3M)
Common Stock Issued00000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(128.5M)(6.3M)(1.76B)(15.1M)0
Financing Cash Flow(128.5M)(6.3M)(140.8M)(497.8M)(76.3M)
Effect of Forex Changes(800K)(6.6M)2.4M(6.7M)4.5M
Net Change in Cash14.3M15.8M(1.8M)9.9M56.1M
Free Cash Flow143.3M28.3M128.1M237.3M88.3M

Fortrea Holdings Inc.

NASDAQ:FTRE

Intrinsic Alpha fair value

Locked

Current Price

$20.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.